A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Levodopa (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms OFF Phenomena; SPAN-PD
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 31 Oct 2017 According to an Acorda Therapeutics media release, company is planning to resubmit the INBRIJA NDA in the fourth quarter of 2017.
    • 29 Aug 2017 According to an Acorda Therapeutics media release, the company is planning a Type A meeting with the FDA to respond to the issues and to seek clarification of what additional information will be required for NDA resubmission.
    • 29 Aug 2017 According to an Acorda Therapeutics media release, the company has received a Refusal to File (RTF) letter from the U.S. FDA regarding its NDA for INBRIJA. In the preliminary review, FDA determined that NDA was not sufficiently complete to permit a substantive review. Reasons for the RTF are the date when the manufacturing site would be ready for inspection and a question regarding the submission of the drug master production record. FDA also requested additional information at resubmission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top